Chagas Disease Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Chagas Disease Management Market
Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. Chagas disease is transmitted by kissing bugs or triatomine bugs. Chagas disease can also transmit through blood transfusions, mother to foetus during pregnancy, and sometimes it causes through organ transplantation. The symptoms of the Chagas disease in early stage include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leads to the heart failure, oesophagus or colon may cause death. The diagnosis of Chagas disease is complicated, require laboratory analysis of blood samples for the detection of antibodies against the Trypanosome cruzi.
The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of Chagas disease management market over the forecast period. In addition, increase in the research and development of new products are one of the main factors that drive the growth of chagas disease management market. However, lack of awareness regarding the chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with chagas disease drugs will hamper the growth of the chagas disease management market over the forecast period.
Chagas disease management market is segmented on the basis of treatment type, drug type, and end user
Based on treatment type, the Chagas disease management market segmented into the following:
Antiparasitic treatment
Symptomatic treatment
Based on drug type, the Chagas disease management market segmented into the following:
Benznidazole
Nifurtimox
Based on the distribution channel, the Chagas disease management market segmented into the following:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Chagas disease management market is still in the budding stage. Currently, very few players are actively involved in the development of new products for the Chagas disease treatment. Currently, there are only two drugs are available in the market for Chagas disease management namely, Benznidazole and Nifurtimox. Several products are in pipeline that may enter the market near future. Increase in research and developments for new products, acquisitions & mergers, collaborations and providing funds to various organizations for research and development activities might fuel the growth of Chagas disease management market. For instance, in March 2012, Dundee University partnered with GSK, Wellcome Trust for neglected tropical disease research. In June 2012, Japan’s Astellas Pharma signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to collaborate on drug discovery research for three neglected tropical diseases: leishmaniasis, Chagas disease, and sleeping sickness. Increase in the incidence Chagas disease in Latin America, and the unavailability of adequate treatment, spell opportunities for pharmaceutical companies across the region to develop new and improved diagnosis and treatment methods over the forecast period.
Geographically, the Chagas disease management market segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Chagas disease is dominant in Latin America region and nowadays it is developing in the rest of world owing to the population mobility from Latin America. According to World Health Organization (WHO), about 8 million people are suffering from Chagas disease in worldwide, and majority of the people living in Latin America region. In addition, about 10,000 people die every year with the Chagas disease. Less number of products available in the market for treatment, and poor diagnostic methods to detect in the Latin America region are the major challenges for the Chagas disease management market in Latin America region. North America and Europe are the key regions for Chagas disease management market owing to increase in the prevalence of Chagas disease according to CDC, approximately 300,000 people are suffering from the Chagas disease in the North America region.
Some of the players in chagas disease management market are AstraZeneca (U.K), Bayer AG (Germany), Daiichi Sankyo Company Ltd (Japan), Eisai Co Ltd (Japan), GlaxoSmithKline Plc. (U.K), Grupo Praxis Pharmaceutical SA (Spain), KaloBios Pharmaceuticals, Inc. (U.S.), Kancera AB (Sweden), Novartis AG (Switzerland), Laboratorio Elea S.A.C.I.F. y A (Argentina), Oblita Therapeutics BVBA (Belgium), and Sanofi Aventis (France) to name a few.
In March 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and leishmaniasis
Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. Chagas disease is transmitted by kissing bugs or triatomine bugs. Chagas disease can also transmit through blood transfusions, mother to foetus during pregnancy, and sometimes it causes through organ transplantation. The symptoms of the Chagas disease in early stage include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leads to the heart failure, oesophagus or colon may cause death. The diagnosis of Chagas disease is complicated, require laboratory analysis of blood samples for the detection of antibodies against the Trypanosome cruzi.
The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of Chagas disease management market over the forecast period. In addition, increase in the research and development of new products are one of the main factors that drive the growth of chagas disease management market. However, lack of awareness regarding the chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with chagas disease drugs will hamper the growth of the chagas disease management market over the forecast period.
Chagas disease management market is segmented on the basis of treatment type, drug type, and end user
Based on treatment type, the Chagas disease management market segmented into the following:
Antiparasitic treatment
Symptomatic treatment
Based on drug type, the Chagas disease management market segmented into the following:
Benznidazole
Nifurtimox
Based on the distribution channel, the Chagas disease management market segmented into the following:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Chagas disease management market is still in the budding stage. Currently, very few players are actively involved in the development of new products for the Chagas disease treatment. Currently, there are only two drugs are available in the market for Chagas disease management namely, Benznidazole and Nifurtimox. Several products are in pipeline that may enter the market near future. Increase in research and developments for new products, acquisitions & mergers, collaborations and providing funds to various organizations for research and development activities might fuel the growth of Chagas disease management market. For instance, in March 2012, Dundee University partnered with GSK, Wellcome Trust for neglected tropical disease research. In June 2012, Japan’s Astellas Pharma signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to collaborate on drug discovery research for three neglected tropical diseases: leishmaniasis, Chagas disease, and sleeping sickness. Increase in the incidence Chagas disease in Latin America, and the unavailability of adequate treatment, spell opportunities for pharmaceutical companies across the region to develop new and improved diagnosis and treatment methods over the forecast period.
Geographically, the Chagas disease management market segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Chagas disease is dominant in Latin America region and nowadays it is developing in the rest of world owing to the population mobility from Latin America. According to World Health Organization (WHO), about 8 million people are suffering from Chagas disease in worldwide, and majority of the people living in Latin America region. In addition, about 10,000 people die every year with the Chagas disease. Less number of products available in the market for treatment, and poor diagnostic methods to detect in the Latin America region are the major challenges for the Chagas disease management market in Latin America region. North America and Europe are the key regions for Chagas disease management market owing to increase in the prevalence of Chagas disease according to CDC, approximately 300,000 people are suffering from the Chagas disease in the North America region.
Some of the players in chagas disease management market are AstraZeneca (U.K), Bayer AG (Germany), Daiichi Sankyo Company Ltd (Japan), Eisai Co Ltd (Japan), GlaxoSmithKline Plc. (U.K), Grupo Praxis Pharmaceutical SA (Spain), KaloBios Pharmaceuticals, Inc. (U.S.), Kancera AB (Sweden), Novartis AG (Switzerland), Laboratorio Elea S.A.C.I.F. y A (Argentina), Oblita Therapeutics BVBA (Belgium), and Sanofi Aventis (France) to name a few.
In March 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and leishmaniasis
1. EXECUTIVE SUMMARY
2. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET INTRODUCTION
2.1. Global Chagas Disease Management Market – Taxonomy
2.2. Global Chagas Disease Management Market –Definitions
2.2.1. Treatment Type
2.2.2. Drug Type
2.2.3. Distribution Channel
3. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Chagas Disease Management Market Dynamic Factors - Impact Analysis
3.6. Global Chagas Disease Management Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Chagas Disease Management Market –Trends
4. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Antiparasitic Treatment
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Symptomatic Treatment
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
6.1. Benznidazole
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Nifurtimox
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Online Pharmacies
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Retail Pharmacies
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Region, 2017 – 2023
9. NORTH AMERICA CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Antiparasitic Treatment
9.1.2. Symptomatic Treatment
9.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Benznidazole
9.2.2. Nifurtimox
9.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Online Pharmacies
9.3.3. Retail Pharmacies
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
9.6. North America Chagas Disease Management Market Dynamics – Trends
10. EUROPE CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Antiparasitic Treatment
10.1.2. Symptomatic Treatment
10.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Benznidazole
10.2.2. Nifurtimox
10.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Online Pharmacies
10.3.3. Retail Pharmacies
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
10.6. Europe Chagas Disease Management Market Dynamics – Trends
11. ASIA-PACIFIC CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Antiparasitic Treatment
11.1.2. Symptomatic Treatment
11.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Benznidazole
11.2.2. Nifurtimox
11.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Online Pharmacies
11.3.3. Retail Pharmacies
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
11.6. Asia-Pacific Chagas Disease Management Market Dynamics – Trends
12. LATIN AMERICA CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Antiparasitic Treatment
12.1.2. Symptomatic Treatment
12.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Benznidazole
12.2.2. Nifurtimox
12.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Online Pharmacies
12.3.3. Retail Pharmacies
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
12.6. Latin America Chagas Disease Management Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Antiparasitic Treatment
13.1.2. Symptomatic Treatment
13.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Benznidazole
13.2.2. Nifurtimox
13.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Online Pharmacies
13.3.3. Retail Pharmacies
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
13.6. MEA Chagas Disease Management Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Treatment Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AstraZeneca (U.K)
14.2.2. Bayer AG (Germany)
14.2.3. Daiichi Sankyo Company Ltd (Japan)
14.2.4. Eisai Co Ltd (Japan)
14.2.5. GlaxoSmithKline Plc. (U.K)
14.2.6. Grupo Praxis Pharmaceutical SA (Spain)
14.2.7. KaloBios Pharmaceuticals, Inc. (U.S.)
14.2.8. Kancera AB (Sweden)
14.2.9. Novartis AG (Switzerland)
14.2.10. Laboratorio Elea S.A.C.I.F. y A (Argentina)
14.2.11. Oblita Therapeutics BVBA (Belgium)
14.2.12. Sanofi (France)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET INTRODUCTION
2.1. Global Chagas Disease Management Market – Taxonomy
2.2. Global Chagas Disease Management Market –Definitions
2.2.1. Treatment Type
2.2.2. Drug Type
2.2.3. Distribution Channel
3. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Chagas Disease Management Market Dynamic Factors - Impact Analysis
3.6. Global Chagas Disease Management Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Chagas Disease Management Market –Trends
4. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Antiparasitic Treatment
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Symptomatic Treatment
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
6.1. Benznidazole
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Nifurtimox
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Online Pharmacies
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Retail Pharmacies
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL CHAGAS DISEASE MANAGEMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Region, 2017 – 2023
9. NORTH AMERICA CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Antiparasitic Treatment
9.1.2. Symptomatic Treatment
9.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Benznidazole
9.2.2. Nifurtimox
9.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Online Pharmacies
9.3.3. Retail Pharmacies
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
9.6. North America Chagas Disease Management Market Dynamics – Trends
10. EUROPE CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Antiparasitic Treatment
10.1.2. Symptomatic Treatment
10.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Benznidazole
10.2.2. Nifurtimox
10.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Online Pharmacies
10.3.3. Retail Pharmacies
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
10.6. Europe Chagas Disease Management Market Dynamics – Trends
11. ASIA-PACIFIC CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Antiparasitic Treatment
11.1.2. Symptomatic Treatment
11.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Benznidazole
11.2.2. Nifurtimox
11.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Online Pharmacies
11.3.3. Retail Pharmacies
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
11.6. Asia-Pacific Chagas Disease Management Market Dynamics – Trends
12. LATIN AMERICA CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Antiparasitic Treatment
12.1.2. Symptomatic Treatment
12.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Benznidazole
12.2.2. Nifurtimox
12.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Online Pharmacies
12.3.3. Retail Pharmacies
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
12.6. Latin America Chagas Disease Management Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA CHAGAS DISEASE MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Treatment Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Antiparasitic Treatment
13.1.2. Symptomatic Treatment
13.2. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Benznidazole
13.2.2. Nifurtimox
13.3. Distribution Channel Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Online Pharmacies
13.3.3. Retail Pharmacies
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Chagas Disease Management Market - Opportunity Analysis Index, By Treatment Type, By Drug, By Distribution Channel and Country, 2017 – 2023
13.6. MEA Chagas Disease Management Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Treatment Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AstraZeneca (U.K)
14.2.2. Bayer AG (Germany)
14.2.3. Daiichi Sankyo Company Ltd (Japan)
14.2.4. Eisai Co Ltd (Japan)
14.2.5. GlaxoSmithKline Plc. (U.K)
14.2.6. Grupo Praxis Pharmaceutical SA (Spain)
14.2.7. KaloBios Pharmaceuticals, Inc. (U.S.)
14.2.8. Kancera AB (Sweden)
14.2.9. Novartis AG (Switzerland)
14.2.10. Laboratorio Elea S.A.C.I.F. y A (Argentina)
14.2.11. Oblita Therapeutics BVBA (Belgium)
14.2.12. Sanofi (France)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
